Skip to main navigation
Skip to search
Skip to main content
Ben-Gurion University Research Portal Home
Help & FAQ
Home
Profiles
Research output
Research units
Prizes
Press/Media
Student theses
Activities
Research Labs / Equipment
Datasets
Projects
Search by expertise, name or affiliation
Ozanimod induction and maintenance treatment for ulcerative colitis
TOUCHSTONE Study Group
Faculty of Health Sciences
Medical School for International Health
Barzilai University Medical Center
Research output
:
Contribution to journal
›
Article
›
peer-review
394
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ozanimod induction and maintenance treatment for ulcerative colitis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Ulcerative Colitis
100%
Maintenance Treatment
100%
Ozanimod
100%
Induction Treatment
100%
Placebo
46%
Clinical Remission
23%
Mayo Clinic Score
23%
High-score
15%
Severe Disease
15%
Clinical Response
15%
Placebo-controlled
7%
Two-dose
7%
Phase II Trial
7%
Placebo Groups
7%
Clinical Efficacy
7%
Moderate to Severe
7%
Anemia
7%
Headache
7%
Adverse Events
7%
Sequestration
7%
Disease Activity
7%
Receptor Subtypes
7%
Daily Dose
7%
Rectal Bleeding
7%
Absolute Lymphocyte Count
7%
Gastrointestinal Tract
7%
Severe Ulcerative Colitis
7%
3-point
7%
Peripheral Lymphocytes
7%
Sphingosine-1-phosphate Receptor (S1PR)
7%
RPC1063
7%
Hierarchical Testing
7%
Activated Lymphocytes
7%
Pharmacology, Toxicology and Pharmaceutical Science
Ulcerative Colitis
100%
Ozanimod
100%
Placebo
57%
Remission
21%
Disease
14%
Adverse Event
7%
Headache
7%
Disease Activity
7%
Rectum Hemorrhage
7%
Sphingosine 1 Phosphate Receptor
7%
Anemia
7%
Receptor Subtype
7%
Immunology and Microbiology
Ulcerative Colitis
100%
Ozanimod
100%
Lymphocyte
7%
Agonist
7%
Lymphocyte Count
7%
Peripheral Blood Lymphocyte
7%
Gastrointestinal Tract
7%